By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Mallinckrodt Pharmaceuticals 

675 McDonnell Boulevard

Hazelwood  Missouri  63042  U.S.A.
Phone: 314-654-2000 Fax: 314-654-5381


SEARCH JOBS

Mallinckrodt is a global business that develops, manufactures, markets and distributes specialty pharmaceutical and biopharmaceutical products and therapies, as well as nuclear imaging products. Areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics and hemostasis products; and central nervous system drugs.

YEAR FOUNDED:

1840

LEADERSHIP:

Founder: Emil Mallinckrodt

CEO: Mark Trudeau

CFO: Matthew Harbaugh

JOBS:

Please click here for Mallinckrodt job opportunities.

PRODUCTS:

All Products


Key Statistics


Email:
Ownership: Subsidiary

Web Site: Mallinckrodt
Employees:
Symbol: MNK
 



Industry
Medical Device


Collaborations

Advanced Magnetics, Inc.  GastroMARK in North America





Company News
Race Heats Up As Mallinckrodt (MNK) Gets Bids 8/9/2017 7:24:07 AM
Mallinckrodt (MNK) Reports Earnings Results for Second Quarter of Fiscal 2017 8/8/2017 12:15:48 PM
Mallinckrodt (MNK) Reports Second Quarter 2017 Results 8/4/2017 8:23:12 AM
Mallinckrodt (MNK) to Snap Up Pennsylvania Drugmaker For Up to $425M 8/4/2017 7:24:37 AM
Mallinckrodt (MNK) Enrolls First Patient In Phase IV Registry Of INOMAX (Nitric Oxide) Gas For Inhalation For Pulmonary Hypertension In Neonates 8/1/2017 8:21:59 AM
Mallinckrodt (MNK) Release: Summary Review Of Clinical And Economic Data On H.P. Acthar Gel (Repository Corticotropin Injection) Published In Advances In Therapy 7/31/2017 9:04:15 AM
U.S. FDA Designates Mallinckrodt (MNK)'s StrataGraft As Regenerative Medicine Advanced Therapy 7/18/2017 11:25:13 AM
Mallinckrodt (MNK) Phase III Terlipressin Trial Achieves Its Enrollment Target Ahead Of Schedule 7/14/2017 7:20:20 AM
FDA Grants Orphan Drug Designation To Mallinckrodt (MNK) Development Product For Potential Treatment Of Duchenne Muscular Dystrophy 7/13/2017 6:40:19 AM
Mallinckrodt (MNK) Finalizes Previously Announced Agreement With DEA And USAOs 7/12/2017 8:36:56 AM
12345678910...
//-->